September 16th 2024
New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.
Trial to evaluate TKI and abiraterone treatment combination for prostate cancer
January 19th 2023“If outcomes are improved for patients who take this combination — or in patients whose cancer is still progressing after being treated with hormone-based chemotherapy alone — this could be a big step forward in caring for these patients," says Moshe Ornstein, MD, MA.
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
January 18th 2023Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Factors for Consideration When Selecting Treatments for Patients with mCRPC
January 18th 2023Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.
How testosterone therapy use in men with prostate cancer has evolved
January 5th 2023Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery. But these men should be closely monitored, they stress.
Olaparib/abiraterone combo approved in European Union for mCRPC
December 21st 2022The European Commission based its approval on results from the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.